RAP media thread., page-3123

In addition to your excellent summary T7 Pfizer should/could be/are more interested in owning a lock down position of the Covid tech more than their half-pie offer (seemingly second thought) for the company. Admittedly they have tossed in an offer for RAP which is most likely going to be rejected. But the license agreement with bells and whistles would be what they need right now...IMHO. Probably, I reckon, rather than in increased offer for RAP they may think they are better served in the medium term simply doing a better license deal with royalties to RAP attached. This way each party can get on with their respective "Best Feet" forward and more lucrative pathways in the faster timeframe. RAP will benefit from a larger (say $12million) upgraded upfront license fee plus a royalty per ? in the course of the Pfizer research and use of the Covid test. RAP would also benefit from their ongoing telehealth Dx (plus Covid?) program which should EXPLODE the revenue within a year or three going forward from here. They both can mix and match use of either tests to suit their chosen methodologies.
MHO DYOR. Pfizer gets rejected...doesn't bother with a higher offer but tosses in a bigger bid/deal offer for the Covid test license etc...ideal? Win Win?